Skip to Content
Merck
All Photos(1)

Key Documents

ALP60

Sigma-Aldrich

Apolipoprotein C-III, human

Synonym(s):

ApoCIII

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352202
eCl@ss:
32160405
NACRES:
NA.41

biological source

human

Quality Level

100
300

Assay

>95% (SDS-PAGE)

form

liquid

manufacturer/tradename

Chemicon®

NCBI accession no.

UniProt accession no.

General description

Apolipoprotein C-III (APOC3) is a multifaceted protein, localized on circulating triglyceride-rich lipoproteins (TRLs), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and very-low-density lipoprotein (VLDL). The APOC3 gene is mapped to the human chromosome 11q23.3. It is mainly expressed in hepatocytes and to a lesser extent in enterocytes.
Product Source: Human plasma tested negative for HBsAg and HIV-I, HIV-II, HBc and Hepatitis C antibodies. All blood products should be treated as potentially infectious.

Application

Apolipoprotein C-III (APOC3), human has been used to determine its effect reconstituted high-density lipoprotein (rHDL) containing apoA-I. It has also been used to test the effects of the exogenous exchangeable apolipoproteins on low-density lipoprotein (LDL) binding to heparin.

Biochem/physiol Actions

Apolipoprotein C-III (APOC3) is involved in triglyceride metabolism and atherosclerotic lesion formation. It also regulates pathological processes involved in atherosclerosis. APOC3 stimulates hypertriglyceridemia (HTG) through various mechanisms. It functions as a lipoprotein lipase (LPL) inhibitor and also interrupts the clearance of triglyceride-rich lipoproteins (TRLs)-remnants. Mutations in the gene lead to lower plasma glycerides and lower cardiovascular disease risk.
The physiological role of Apo CIII is unknown. It is suggested that Apo CIII may inhibit the activation of lipoprotein lipase by Apo CII.

Physical form

Liquid in 10 mM NH4HCO3, pH 7.4.

Storage and Stability

Maintain at -20ºC or below in undiluted aliquots for up to 12 months. Avoid repeated freeze/thaw cycles. All blood products should be treated as potentially infectious.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Storage Class Code

12 - Non Combustible Liquids

WGK

nwg

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Kyung-Hyun Cho
Molecules and cells, 27(3), 291-297 (2009-03-28)
Apolipoprotein (apo) C-III is a marker protein of triacylglycerol (TG)-rich lipoproteins and high-density lipoproteins (HDL), and has been proposed as a risk factor of coronary heart disease. To compare the physiologic role of reconstituted HDL (rHDL) with or without apoC-III
Jihoe Kim et al.
BMB reports, 43(8), 535-540 (2010-08-28)
Patients with hemorrhagic fever with renal syndrome (HFRS) often exhibit altered serum lipid and lipoprotein profile during the oliguric phase of the disease. Serum lipid and lipoprotein profiles were assessed during the oliguric and recovery phases in six male patients
Alison B Kohan
Current opinion in endocrinology, diabetes, and obesity, 22(2), 119-125 (2015-02-19)
The purpose of this article is to summarize the recent epidemiological, basic science, and pharmaceutical research linking apolipoprotein C-III (apoC-III) with the development and treatment of cardiovascular disease (CVD). ApoC-III is an important emerging target linking hypertriglyceridemia with CVD. ApoC-III
Jan Borén et al.
Frontiers in endocrinology, 11, 474-474 (2020-08-28)
Cardiovascular disease (CVD) is the leading cause of death globally. It is well-established based on evidence accrued during the last three decades that high plasma concentrations of cholesterol-rich atherogenic lipoproteins are causatively linked to CVD, and that lowering these reduces
Mengdie Luo et al.
Lipids in health and disease, 15(1), 184-184 (2016-10-25)
Apolipoprotein C-III has been referred to as an important participant in the metabolism of triglyceride-rich lipoproteins, leading to hypertriglyceridemia and thereafter cardiovascular disease. Accumulating evidence indicates that apolipoprotein C-III is a multifaceted protein which not only regulates triglyceride metabolism, but

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service